FMP
BioVie Inc.
BIVI
NASDAQ
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
1.9 USD
-0.18 (-9.47%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Cuong Viet Do M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://bioviepharma.comexchange
NASDAQ
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to Bio...
CIK
0001580149
ISIN
US09074F2074
CUSIP
09074F207
Address
680 West Nye Lane
Phone
775 888 3162
Country
US
Employee
14
IPO Date
Sep 18, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
BIVI Financial Summary
CIK
0001580149
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
09074F207
ISIN
US09074F2074
Country
US
Price
1.9
Beta
0.9
Volume Avg.
6.14M
Market Cap
33.76M
Shares
-
52-Week
1.04-33.1
DCF
3.92
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.37
P/B
-
Website
https://bioviepharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BIVI News
It looks like there's no news available.
